FDAnews Drug Daily Bulletin

Glaxo Joins J&J in $200 Million Fund With Index Ventures

A A
GlaxoSmithKline and Johnson & Johnson are forming a $200 million fund with index ventures to invest in early-stage biotechnology companies, a move that may entice venture capitalists back to the industry.
Bloomberg